Literature DB >> 33977378

ERCP within 6 or 12 h for acute cholangitis: a propensity score-matched analysis.

Aymeric Becq1,2, Madhuri Chandnani1,2, Anthony Bartley1,2, Alexandre Nuzzo3, Mohammad Bilal1,2, Shishira Bharadwaj1,2, Jonah Cohen1,2, Moamen Gabr1,2, Tyler M Berzin1,2, Douglas K Pleskow1,2, Mandeep S Sawhney4,5.   

Abstract

BACKGROUND: The optimal timing of biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) for patients with acute cholangitis remains controversial. The aim of our study was to determine if ERCP performed within 6 or 12 h of presentation was associated with improved clinical outcomes.
METHODS: Medical records for all patients with acute cholangitis who underwent ERCP at our institution between 2009 and 2018 were reviewed. Outcomes were compared between those who underwent ERCP within or after 12 h using propensity score framework. Our primary outcome was length of hospitalization. Secondary outcomes included in-hospital mortality, adverse events, ERCP failure, length of ICU stay, organ failure, recurrent cholangitis, and 30-day readmission. In secondary analysis, outcomes for ERCP done within or after 6 h were also compared.
RESULTS: During study period, 487 patients with cholangitis were identified, of whom 147 had ERCP within 12 h of presentation. Using propensity score matching, we selected 145 pairs of patients with similar characteristics. Length of hospitalization was similar between ERCP within or after 12 h (135.9 vs 122.1 h, p 0.094). No difference was noted in mortality, ERCP failure, adverse events, need and length of ICU stay, and recurrent cholangitis. However, 30-day readmission rates were lower when ERCP within 12 h (7.6 vs 15.2, p 0.042). No significant difference was noted in aforementioned outcomes between ERCP performed within or after 6 h.
CONCLUSIONS: ERCP performed within 6 h or 12 h of presentation was not associated with superior clinical outcomes, however, may result in reduced re-hospitalization.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholangitis; ERCP; Length of hospitalization; Timing; Tokyo score

Mesh:

Year:  2021        PMID: 33977378     DOI: 10.1007/s00464-021-08523-w

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  15 in total

1.  Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.

Authors:  Anne F Peery; Seth D Crockett; Alfred S Barritt; Evan S Dellon; Swathi Eluri; Lisa M Gangarosa; Elizabeth T Jensen; Jennifer L Lund; Sarina Pasricha; Thomas Runge; Monica Schmidt; Nicholas J Shaheen; Robert S Sandler
Journal:  Gastroenterology       Date:  2015-08-29       Impact factor: 22.682

2.  Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline.

Authors:  Gianpiero Manes; Gregorios Paspatis; Lars Aabakken; Andrea Anderloni; Marianna Arvanitakis; Philippe Ah-Soune; Marc Barthet; Dirk Domagk; Jean-Marc Dumonceau; Jean-Francois Gigot; Istvan Hritz; George Karamanolis; Andrea Laghi; Alberto Mariani; Konstantina Paraskeva; Jürgen Pohl; Thierry Ponchon; Fredrik Swahn; Rinze W F Ter Steege; Andrea Tringali; Antonios Vezakis; Earl J Williams; Jeanin E van Hooft
Journal:  Endoscopy       Date:  2019-04-03       Impact factor: 10.093

3.  Reply to Letter: "Cost-Effective Decisions in Managing Silent Common Bile Duct Stones Should Include all the Management Options to Help Decision Makers".

Authors:  Susie X Sun; Afif N Kulaylat; Christopher S Hollenbeak; David I Soybel
Journal:  Ann Surg       Date:  2017-12       Impact factor: 12.969

4.  Delayed endoscopic retrograde cholangiopancreatography is associated with persistent organ failure in hospitalised patients with acute cholangitis.

Authors:  F Lee; E Ohanian; J Rheem; L Laine; K Che; J J Kim
Journal:  Aliment Pharmacol Ther       Date:  2015-05-22       Impact factor: 8.171

5.  Optimal Timing of Endoscopic Retrograde Cholangiopancreatography in Acute Cholangitis.

Authors:  Linda A Hou; Loren Laine; Nima Motamedi; Ara Sahakian; Christianne Lane; James Buxbaum
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

6.  Association of Admission Laboratory Values and the Timing of Endoscopic Retrograde Cholangiopancreatography With Clinical Outcomes in Acute Cholangitis.

Authors:  Alexander C Schwed; Monica M Boggs; Xuan-Binh D Pham; Drew M Watanabe; Michael C Bermudez; Amy H Kaji; Dennis Y Kim; David S Plurad; Darin J Saltzman; Christian de Virgilio
Journal:  JAMA Surg       Date:  2016-11-01       Impact factor: 14.766

7.  Outcomes Associated With Timing of ERCP in Acute Cholangitis Secondary to Choledocholithiasis.

Authors:  Malav P Parikh; Vaibhav Wadhwa; Prashanthi N Thota; Rocio Lopez; Madhusudhan R Sanaka
Journal:  J Clin Gastroenterol       Date:  2018 Nov/Dec       Impact factor: 3.062

8.  Early diagnosis and treatment of severe acute cholangitis.

Authors:  Wei-Zhong Zhang; Yi-Shao Chen; Jin-Wei Wang; Xue-Rong Chen
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

9.  Association between early ERCP and mortality in patients with acute cholangitis.

Authors:  Ming Tan; Ove B Schaffalitzky de Muckadell; Stig B Laursen
Journal:  Gastrointest Endosc       Date:  2017-04-20       Impact factor: 9.427

10.  Mortality Risk for Acute Cholangitis (MAC): a risk prediction model for in-hospital mortality in patients with acute cholangitis.

Authors:  Jochen Schneider; Alexander Hapfelmeier; Sieglinde Thöres; Andreas Obermeier; Christoph Schulz; Dominik Pförringer; Simon Nennstiel; Christoph Spinner; Roland M Schmid; Hana Algül; Wolfgang Huber; Andreas Weber
Journal:  BMC Gastroenterol       Date:  2016-02-09       Impact factor: 3.067

View more
  1 in total

Review 1.  Optimal timing of biliary drainage based on the severity of acute cholangitis: A single-center retrospective cohort study.

Authors:  Zhao-Qing Lu; Han-Yu Zhang; Chen-Fen Su; Yue-Yan Xing; Guo-Xing Wang; Chun-Sheng Li
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.